Table 1.
Exosomal miRNA role in the diagnosis of prostatic cancer (PC).
| Exosomal cargo | Cargo type | Origin or cell source | Biomarker or other roles | Number of patients | Year | Ref. |
|---|---|---|---|---|---|---|
| Glypican-1 | Protein (heparan sulfate proteoglycans) | Serum | 1) Diagnostic biomarker for dividing PC 2) Benign pancreatic disease biomarker 3) Prediction of prognosis |
190 | 2015 | (123) |
| Exosomal integrin | Protein (adhesion) | N/A | Prognostic | 27 | 2010 | (124) |
| Migration inhibitory factor (MIF) | Protein (cytokine) | 1) Plasma 2) Serum |
Liver metastasis prognostic marker | 40 | 2015 | (61) |
| Sox2ot | lncRNA | Peripheral blood | Early diagnosis | 61 | 2018 | (125) |
| MALAT-1 | lncRNA | Peripheral blood | Early diagnosis | N/A | 2020 | (126) |
| HULC | lncRNA | Peripheral blood | Early diagnosis | N/A | 2020 | (126) |
| GPC1 | mRNA | Peripheral blood | 1) Early PC diagnosis 2) Tumor stage |
133 | 2017 | (127) |
| WASF2 | mRNA | Serum | 1) Early PC diagnosis 2) Tumor stage |
27 | 2019 | (128) |
| IARS | circRNA | 1) Culture medium 2) Peripheral blood |
1) Tumor stage 2) Survival evaluation |
92 | 2018 | (129) |